HPLC purity
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
Vial illustrations reflect supplied lyophilized format. Distribution scope and destination market confirmed before invoicing.
| Compound | ACE-031 |
|---|---|
| CAS number | 1169766-01-1 |
| Class | Growth-hormone axis & repair |
| Molecular weight | ≈77.24 kDa (calculated ActRIIB-Fc homodimer; glycosylated native runs ~90–100 kDa apparent) |
| Form | Lyophilized powder, sterile glass vial |
| Purity target | ≥ 98% by HPLC |
| Vial formats | 1mg |
| Documentation | COA + HPLC + MS, batch lot file where available |
| Distribution scope | Research use, worldwide |
| Storage | Store lyophilized ACE-031 at -20°C, protected from light and moisture. After reconstitution, keep at 2-8°C for near-term research use or aliquot and freeze at -20°C to -80°C to minimize freeze-thaw cycles. Follow lot-specific handling stated on the COA. |
| Tier | Quantity | Lead time |
|---|---|---|
| Sample lot | From 50 vials | 3–7 days |
| Production lot | 200–1,000 vials | 10–14 days |
| OEM repeat | 1,000+ vials | 14–18 days, scheduled |
ACE-031 (ramatercept) is a recombinant soluble activin receptor type IIB (ActRIIB)–IgG1 Fc fusion protein that acts as a myostatin/activin ligand trap, supplied by Pepti as research-use material in 1 mg vials.
Documentation
COA / HPLC / MS document support where available. Distribution scope confirmed before invoicing.
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
Mass spectrometry identity confirmation against the ACE-031 reference profile.
Compound prefix and lot serial printed on the vial label and repeated in the document pack and carton.
FAQ
ACE-031 (ramatercept) is a recombinant Fc-fusion protein of roughly 77 kDa (a glycosylated ActRIIB-Fc homodimer), not a short synthetic peptide. It is produced in a mammalian expression system and handled as a biologic; lot-specific identity and mass are documented on the COA.
Each lot is supplied with a Certificate of Analysis covering identity (mass spec), purity (HPLC and SDS-PAGE), and standard protein-release checks. Endotoxin, appearance, and reconstitution notes can be added on request, and analytical traces are available under RFQ/NDA for OEM buyers.
Catalog format is 1 mg per vial with a minimum order of 50 vials. Bulk quantities, custom fill volumes, and private-label/OEM packaging (custom vials, labels, and kit configurations) are available on request with volume-based pricing.
No. ACE-031 is offered strictly for laboratory research use. Clinical development of ramatercept was discontinued, and the material is not intended for human, veterinary, therapeutic, or diagnostic use. Buyers are responsible for compliance with their local regulations.
Yes. The compound resolves to ramatercept, CAS 1169766-01-1, with a reported molecular weight near 77 kDa for the ActRIIB-Fc construct. We provide the current spec sheet and a representative COA on request so your team can verify identity and purity before purchase.
Related compounds